New Hope for Migraine Sufferers
Posted on: Thursday, 17 April 2008, 12:00 CDT
At the American Academy of Neurology Annual Meeting, Optinose, the Norwegian drug delivery specialists, today presented Phase I data that could lead to faster, effective and less invasive relief for migraine sufferers. The recently completed trial first demonstrated that Sumatriptan powder delivered intranasally using OptiNose's 2nd generation device has a rapid onset of action and is as effective as subcutaneously administered Sumatriptan in preventing GTN Challenge Induced EEG changes in migraine sufferers.
Optinose CEO Helena Djupesland commented: "There has been great interest in nasal delivery of migraine medications as a way of accelerating onset of action. However progress has been held back by inadequate and variable clinical efficacy, together with side effects such as a bitter aftertaste. The breath-actuated OptiNose device represents a major advance by delivering the drug dose primarily to the highly vascularized mucosa beyond the nasal valve and accelerating onset of action. In our trial, pharmacokinetics data showed that Sumatriptan powder at doses of 10 mg or 20 mg delivered intranasally by the OptiNose device was rapidly absorbed with a median tmax of 20 min, which is 70 minutes earlier than the marketed sumatriptan nasal spray. There were no reports of bad aftertaste. Regarding efficiacy, the trial showed that the mean qEEG changes for Optinose Intrasanal Sumatriptan powder are similar to SC. We now look forward to presenting further Phase II data later in 2008."
Source: Business Wire
Related Articles
- Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting
- Pervasis Therapeutics Presents Safety Data From Phase 1 and 2 Clinical Trials of Vascugel(R) at the American Society of Nephrology Annual Meeting
- CuraGen Reports Encouraging Preliminary Data From Phase II Melanoma Trial
- Data From Phase II Clinical Trial of Galiximab in Combination With Rituximab in Patients With Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma
- New Data From Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting
- GPC Biotech Announces Data From Several Satraplatin Clinical Trials to Be Presented at ASCO Annual Meeting
- Positive Data From ASA404 Prostate Cancer Trial Presented at ASCO
- Genitope Corporation to Host Conference Call to Discuss Updated Blinded Data From Its Phase 3 Clinical Trial
- Indevus Announces Positive Data From Second Phase III Trial for SANCTURA XR(TM) in Overactive Bladder
- Idenix Pharmaceuticals Reports Positive 4-Week Data From A Phase IIb Clinical Trial Evaluating Valopicitabine (NM283) Combined With Pegylated Interferon in Treatment-Naive Hepatitis C Patients
 |
 |
User Comments (0)
RSS Feeds